Gonzalo Venegas, MD
Obstetrics & Gynecology · Dallas, TXNPI 1730112988
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 24.6% of the total. Reporting peaked in 2021 at $572 and has fallen 62.4% since, to $215 in 2025.
Across 80 payments — averaging $27.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$533
- Aspira Women's Health Inc$420
- Astellas Pharma US Inc$144
- Minerva Surgical, Inc$142
- Myovant Sciences Inc.$124
- Lupin Inc.$103
- plus $702 from 20 others
Across 36 payments — averaging $1345.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$48K
What the payments were for
- Consulting fees$432%
- Food & beverage$2,01593%
- Education$1115%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $533 |
| Aspira Women's Health Inc | 9 | $420 |
| Astellas Pharma US Inc | 3 | $144 |
| Minerva Surgical, Inc | 1 | $142 |
| Myovant Sciences Inc. | 1 | $124 |
| Lupin Inc. | 6 | $103 |
| Pfizer | 4 | $91 |
| Exeltis, USA Inc. | 5 | $90 |
| Kerecis Limited | 1 | $79 |
| Sumitomo Pharma America, Inc. | 2 | $69 |
| Mylan Pharmaceuticals Inc. | 3 | $50 |
| Organon | 2 | $47 |
| Mayne Pharma Commercial LLC | 3 | $39 |
| Smith+Nephew | 1 | $28 |
| Cumberland Pharmaceuticals, Inc. | 2 | $26 |
| Mission Pharmacal Company | 2 | $26 |
| Innovation Technologies Inc | 1 | $25 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Roche Diagnostics Corporation | 1 | $16 |
| Sage Therapeutics, LLC | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $15 |
| Avion Pharmaceuticals | 1 | $15 |
| Bayer | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,168 in reported general payments places this provider in the 65th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 61 | $2,253 |
| Terconazole | 12 | $366 |
| Solifenacin Succinate | 14 | $341 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Dallas
- Dale StovallDallas$590K
- Quanita CrableDallas$176K
- Kamilia SmithDallas$119K
- Yolanda LawsonDallas$96K
- Patrick WeixDallas$96K
- David RogersDallas$44K
- Devin GarzaAustin$2M
- Shawn TassoneAustin$1.3M
- Karyn-Anne CumberbatchMissouri City$452K
- Robert AsgharianEl Paso$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.